Cyclin-dependent kinase 8 (cdk8) inhibitor (IC50
= 280 nM). Also binds to cdk19 in an ATP-competitive manner. Inhibits p21-induced transcription. Reverses doxorubicin
-induced tumor-promoting paracrine activities in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Senex Biotechnology.
Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities.
Porter, Donald C, Farmaki, Elena, Altilia, Serena, Schools, Gary P, West, Deborah, Chen, Mengqian, Chang, Bey-Dih, Puzyrev, Anatoliy, Lim, Chang-uk, Rokow-Kittell, Rebecca, Friedhoff, Lawrence, Papavassiliou, Athanasi, Kalurupalle, Swathi, Hurteau, Gregory, Shi, Jun, Baran, Phil S, Gyorffy, Balazs, Wentland, Mark P, Broude, Eugenia, Kiaris, Hippokra, Roninson, Igor B
Proc Natl Acad Sci U S A, 2012;109(34):13799-804.